US Patent 11155630 Therapeutic antibodies and their uses
Patent 11155630 was granted and assigned to Pfizer on October, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 2 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+310 characters)
Article
Patent abstract
The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 6 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111556300
Date of Patent
October 26, 2021
0Patent Application Number
202012210
Date Filed
December 21, 2020
0Official Website
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111556300
Date of Patent
October 26, 2021
0Patent Application Number
202012210
Date Filed
December 21, 2020
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 27 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11155630 Therapeutic antibodies and their uses
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11155630
Date of patent
October 26, 2021
Patent application number
20201221
Date Filed
December 21, 2020
Find more entities like US Patent 11155630 Therapeutic antibodies and their uses
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.